# VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

> **NCT02146222** · PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 14 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** VEGFR/PDGFR dual kinase inhibitor X-82
- **DRUG:** docetaxel
- **OTHER:** fluorine F 18 fluorothymidine
- **PROCEDURE:** positron emission tomography/computed tomography
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02146222
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02146222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02146222, "VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02146222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*